Nuevocor Welcomes Dr. Thierry Abribat to its Board of Directors Nuevocor, a Singapore biotech firm, announces the appointment of Dr. Thierry Abribat to its Board, enhancing its leadership in gene therapy for cardiomyopathies.

Nuevocor Welcomes Dr. Thierry Abribat to its Board of Directors #Singapore #Nuevocor #biotech_company #Thierry_Abribat

Nuevocor Secures $45 Million to Advance Innovative Cardiomyopathy Treatment Nuevocor, based in Singapore, has raised $45 million to fund clinical trials for its breakthrough mechanobiology therapy for cardiomyopathy. This new funding aims to transform treatment options for patients suffering from LMNA-related conditions.

Nuevocor Secures $45 Million to Advance Innovative Cardiomyopathy Treatment #Singapore #Nuevocor #NVC-001 #Cardiomyopathy

Nuevocor Appoints Andreas Wallnöfer as Chairman of Board to Steer Biotechnology Innovations Nuevocor has recently appointed Dr. Andreas Wallnöfer as the Chairman of its Board of Directors, enhancing leadership in cardiomyopathy treatments.

Nuevocor Appoints Andreas Wallnöfer as Chairman of Board to Steer Biotechnology Innovations #Singapore #Philadelphia #biotechnology #Andreas_Wallnöfer #Nuevocor